Clinical Resources
Materials for Providers
Alphabetical by Title
Standing Orders for Administering Recombinant Zoster Vaccine (Shingrix) to Adults
Eligible healthcare professionals may vaccinate adults who meet any of the criteria on this form
Materials for Vaccine Recipients
Alphabetical by Title
Shingles (Zoster): Questions and Answers
Information about the disease and vaccines for patients
Ask the Experts
CDC · FDA · State
ACIP Recommendations
Current Recommendations
ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022
MMWR, January 21, 2022, 71(3);80-84
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
MMWR, January 26, 2018; 67(3); 103–108
Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, June 6, 2008; 57(05):1-30
Additional Federal Resources
- All current and archived ACIP Zoster (Shingles) recommendations
- General Best Practice Guidelines for Immunization
- ACIP Zoster (Shingles) recommendations at CDC
- CDC Zoster (Shingles) Information for Healthcare Professionals
- Clinical Considerations for Use of Recombinant Zoster Vaccine (RZV, Shingrix) in Immunocompromised Adults ≥19 Years
Vaccine Information Statements
Zoster, Recombinant VIS
Updated: February 4, 2022
CDC Recommended Schedules
2025 Child and Adolescent Immunization Schedule
- Page count: 17
- Color
- Size: 8.5 ” x 11″
2025 Adult Immunization Schedule
- Page count: 15
- Color
- Size: 8.5 ” x 11″
FDA Package Inserts & EUAs
Zoster (shingles): Shingrix Package Insert
GSK
More from Immunize.org
Unprotected People Stories
In the United States, there are about one million cases… read more
